Skip to main content
DLBCL staging may affect risk of secondary primary malignancies

Individuals with early-stage diffuse large B-cell lymphoma had an insignificantly higher likelihood of developing secondary primary malignancies after a median follow-up of 13.3 years, and increased odds of developing breast, colorectal, pancreatic and prostate SPMs during the first five years post-diagnosis, compared with those with advanced stage DLBCL, researchers reported in the journal Cancer. However, the findings showed that hematologic SPMs were more likely among those with advanced DLBCL at 10 to 15 years post-diagnosis, while SPMs were associated with significantly higher mortality risk, regardless of disease stage at diagnosis.

Full Story: